Literature DB >> 32327527

Epigenetic mechanisms and metabolic reprogramming in fibrogenesis: dual targeting of G9a and DNMT1 for the inhibition of liver fibrosis.

Marina Barcena-Varela1, Hannah Paish2, Laura Alvarez1, Iker Uriarte1,3, Maria U Latasa1, Eva Santamaria1,3, Miriam Recalde1, Maria Garate1, Alex Claveria1, Leticia Colyn1, Maria Arechederra1, Maria J Iraburu4, Malgorzata Milkiewicz5, Piotr Milkiewicz6, Bruno Sangro3,7, Stuart M Robinson8, Jeremy French8, Ana Pardo-Saganta9, Julen Oyarzabal10, Felipe Prosper11, Krista Rombouts12, Fiona Oakley2, Jelena Mann2, Carmen Berasain1,3, Matias A Avila13,3, Maite G Fernandez-Barrena14,15.   

Abstract

OBJECTIVE: Hepatic stellate cells (HSC) transdifferentiation into myofibroblasts is central to fibrogenesis. Epigenetic mechanisms, including histone and DNA methylation, play a key role in this process. Concerted action between histone and DNA-mehyltransferases like G9a and DNMT1 is a common theme in gene expression regulation. We aimed to study the efficacy of CM272, a first-in-class dual and reversible G9a/DNMT1 inhibitor, in halting fibrogenesis.
DESIGN: G9a and DNMT1 were analysed in cirrhotic human livers, mouse models of liver fibrosis and cultured mouse HSC. G9a and DNMT1 expression was knocked down or inhibited with CM272 in human HSC (hHSC), and transcriptomic responses to transforming growth factor-β1 (TGFβ1) were examined. Glycolytic metabolism and mitochondrial function were analysed with Seahorse-XF technology. Gene expression regulation was analysed by chromatin immunoprecipitation and methylation-specific PCR. Antifibrogenic activity and safety of CM272 were studied in mouse chronic CCl4 administration and bile duct ligation (BDL), and in human precision-cut liver slices (PCLSs) in a new bioreactor technology.
RESULTS: G9a and DNMT1 were detected in stromal cells in areas of active fibrosis in human and mouse livers. G9a and DNMT1 expression was induced during mouse HSC activation, and TGFβ1 triggered their chromatin recruitment in hHSC. G9a/DNMT1 knockdown and CM272 inhibited TGFβ1 fibrogenic responses in hHSC. TGFβ1-mediated profibrogenic metabolic reprogramming was abrogated by CM272, which restored gluconeogenic gene expression and mitochondrial function through on-target epigenetic effects. CM272 inhibited fibrogenesis in mice and PCLSs without toxicity.
CONCLUSIONS: Dual G9a/DNMT1 inhibition by compounds like CM272 may be a novel therapeutic strategy for treating liver fibrosis. © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  fibrogenesis; gene regulation; glucose metabolism

Year:  2020        PMID: 32327527     DOI: 10.1136/gutjnl-2019-320205

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  20 in total

Review 1.  Macrophages in Chronic Liver Failure: Diversity, Plasticity and Therapeutic Targeting.

Authors:  Arjuna Singanayagam; Evangelos Triantafyllou
Journal:  Front Immunol       Date:  2021-04-02       Impact factor: 7.561

2.  New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming.

Authors:  Leticia Colyn; Gloria Alvarez-Sola; M Ujue Latasa; Carmen Berasain; Maite G Fernandez-Barrena; Matias A Avila; Iker Uriarte; Jose M Herranz; Maria Arechederra; George Vlachogiannis; Colin Rae; Antonio Pineda-Lucena; Andrea Casadei-Gardini; Federica Pedica; Luca Aldrighetti; Angeles López-López; Angeles López-Gonzálvez; Coral Barbas; Sergio Ciordia; Sebastiaan M Van Liempd; Juan M Falcón-Pérez; Jesus Urman; Bruno Sangro; Silve Vicent; Maria J Iraburu; Felipe Prosper; Leonard J Nelson; Jesus M Banales; Maria Luz Martinez-Chantar; Jose J G Marin; Chiara Braconi; Christian Trautwein; Fernando J Corrales; F Javier Cubero
Journal:  J Exp Clin Cancer Res       Date:  2022-05-26

3.  Gpx3 and Egr1 Are Involved in Regulating the Differentiation Fate of Cardiac Fibroblasts under Pressure Overload.

Authors:  Guoxing Li; Yuhong Qin; Zhe Cheng; Xiaocheng Cheng; Ruiyu Wang; Xuexiu Luo; Yipin Zhao; Dongying Zhang; Gang Li
Journal:  Oxid Med Cell Longev       Date:  2022-06-28       Impact factor: 7.310

Review 4.  The Power of Plasticity-Metabolic Regulation of Hepatic Stellate Cells.

Authors:  Parth Trivedi; Shuang Wang; Scott L Friedman
Journal:  Cell Metab       Date:  2020-11-23       Impact factor: 27.287

Review 5.  Best Practices and Progress in Precision-Cut Liver Slice Cultures.

Authors:  Liza Dewyse; Hendrik Reynaert; Leo A van Grunsven
Journal:  Int J Mol Sci       Date:  2021-07-01       Impact factor: 5.923

6.  Signal Transduction and Molecular Regulation in Fatty Liver Disease.

Authors:  Xiaocheng Charlie Dong; Kushan Chowdhury; Menghao Huang; Hyeong Geug Kim
Journal:  Antioxid Redox Signal       Date:  2021-06-03       Impact factor: 7.468

7.  Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis.

Authors:  Alex Claveria-Cabello; Leticia Colyn; Iker Uriarte; Maria Ujue Latasa; Maria Arechederra; Jose M Herranz; Laura Alvarez; Jesus M Urman; Maria L Martinez-Chantar; Jesus M Banales; Bruno Sangro; Krista Rombouts; Julen Oyarzabal; Jose J G Marin; Carmen Berasain; Matias A Avila; Maite G Fernandez-Barrena
Journal:  Cancers (Basel)       Date:  2020-12-13       Impact factor: 6.639

8.  Histone Methyltransferase G9a-Promoted Progression of Hepatocellular Carcinoma Is Targeted by Liver-Specific Hsa-miR-122.

Authors:  Lan-Ting Yuan; Wei-Jiunn Lee; Yi-Chieh Yang; Bo-Rong Chen; Ching-Yao Yang; Min-Wei Chen; Ji-Qing Chen; Michael Hsiao; Ming-Hsien Chien; Kuo-Tai Hua
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

Review 9.  Epigenetics in Liver Fibrosis: Could HDACs be a Therapeutic Target?

Authors:  Alex Claveria-Cabello; Leticia Colyn; Maria Arechederra; Jesus M Urman; Carmen Berasain; Matias A Avila; Maite G Fernandez-Barrena
Journal:  Cells       Date:  2020-10-19       Impact factor: 6.600

10.  TGF-β1 is a regulator of the pyruvate dehydrogenase complex in fibroblasts.

Authors:  Edward R Smith; Timothy D Hewitson
Journal:  Sci Rep       Date:  2020-10-21       Impact factor: 4.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.